Banner - NPPA Connect

NP/PA Connect
News
Media
Conferences
Events
Publication
CME/CE
Resources
Editorial Advisory Board
Partners
Subscribe

Opinion|Videos|July 11, 2024

Head-to-Head Clinical Trials: Comparing Psoriasis Treatment Response Rates

Author(s)Alexa Hetzel, MS, PA-C, Andrew Mastro, MS, PA-C , TJ Chao, MPAS, PA-C

This professional summary discusses the definitions of loss of response and loss of efficacy in patient therapy, while also comparing response rates across different psoriasis treatments.

Episodes in this series

4 KOLs are featured on this panel.

EP. 1 Navigating Plaque Psoriasis: Insights into the Psychosocial Impact and Evolving Treatment Landscape

4 KOLs are featured on this panel.

EP. 2 Plaque Psoriasis Case Study: Patient Presentation, Treatment Selection, and Shared Decision-Making for Improved Outcomes

4 KOLs are featured on this panel.

EP. 3 Empowering Patients with Plaque Psoriasis: Navigating Treatment Challenges Informed Patient Conversations and Decision Trees

4 KOLs are featured on this panel.

EP. 4 A Conversation on Combination Therapy, Safety Profiles, and Targeted IL-17 Systemic Treatments

4 KOLs are featured on this panel.

EP. 5 Clinical Insights: Managing Psoriasis Treatment Dynamics and Strategic Therapy Switching Considerations

4 KOLs are featured on this panel.

EP. 6 Head-to-Head Clinical Trials: Comparing Psoriasis Treatment Response Rates

4 KOLs are featured on this panel.

EP. 7 TYK2 Inhibition and Deucravacitinib: Mechanism of Action, Safety Considerations, and Patient-Provider Conversations

4 KOLs are featured on this panel.

EP. 8 Comparative Analysis: Deucravacitinib and Adalimumab in Psoriasis Treatment

4 KOLs are featured on this panel.

EP. 9 Understanding IL-17 Therapies: Treatment Considerations, Rapid Response, and Impact on Plaque Psoriasis Location

4 KOLs are featured on this panel.

EP. 10 Expert Insights into Managing Inadequate Response to Systemic Therapies: Strategies and Solutions

4 KOLs are featured on this panel.

EP. 11 Long-Term Efficacy and Insights from POETYK PSO-1 Studies: Implications for Psoriasis Treatment

4 KOLs are featured on this panel.

EP. 12 Achieving Durable Responses: Physician's Guide to Interpreting Long-Term Efficacy Data

4 KOLs are featured on this panel.

EP. 13 When to Discontinue Treatment: Interpreting Safety Signals and Adverse Event Patterns

4 KOLs are featured on this panel.

EP. 14 Updating Treatment Guidelines: Incorporating Novel Therapies to Address Unmet Needs

EP. 15 Available Psoriasis, Patient Involvement, and Holistic Treatment

EP. 15 Available Psoriasis, Patient Involvement, and Holistic Treatment

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Related Content

1 expert is featured in this series

Case 1: Choosing Non-Steroidal Topicals for Intertriginous Psoriasis

ByTina Bhutani-Jacques, MD

July 20th 2026

1 expert is featured in this series

The Ongoing Role of Topical Therapy in Plaque Psoriasis Management

ByTina Bhutani-Jacques, MD

July 20th 2026

2 experts are featured in this series

The Safety of Advanced Topical Therapies in Inflammatory Dermatoses

ByPeter Lio, MD,Alexandra K. Golant, MD

July 15th 2026

2 experts are featured in this series

Understanding Corticosteroid-Related Medical-Legal Risks in Inflammatory Dermatoses

ByPeter Lio, MD,Alexandra K. Golant, MD

July 15th 2026

Setting Expectations: Treatment Timelines, Adherence, and Monitoring in Vitiligo

ByNada Elbuluk, MD, MSc, FAAD,Susan Taylor, MD, FAAD

July 14th 2026

Latest CME

Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis

Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis

Johann Gudjonsson, MD, PhD; Christopher Bunick, MD, PhD

Navigating Safety Data with Janus Kinase (JAK) Inhibitors in Atopic Dermatitis (AD) Management

Navigating Safety Data with Janus Kinase (JAK) Inhibitors in Atopic Dermatitis (AD) Management

Andrew Alexis, MD, MPH; Leon Kircik, MD

Burst CME™: Optimizing Care for Patients with Psoriasis – Incorporating a Buy-and-Bill Model for Biologic Agents into Dermatological Practice

Burst CME™: Optimizing Care for Patients with Psoriasis – Incorporating a Buy-and-Bill Model for Biologic Agents into Dermatological Practice

Jerry Bagel, MD, MS

Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient

Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient

Douglas DiRuggiero, DMSc, MHS, PA-C; Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP

Patient, Provider, and Caregiver Connection™: Addressing Patient Challenges With Holistic Approaches to Vitiligo Management

Patient, Provider, and Caregiver Connection™: Addressing Patient Challenges With Holistic Approaches to Vitiligo Management

Andrew F. Alexis, MD, MPH; Chesahna Kindred, MD, MBA, FAAD

Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches

Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches

Hadar Lev-Tov, MD; Martina Porter, MD

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Trending on Dermatology Times

New Review Confirms How Nonmedicated Skin Care Vehicles Drive Clinical Improvement

Zasocitinib Shows High Skin Clearance at Hard-to-Treat Psoriasis Sites

Dermatology Times Spot Test: July 19, 2026

Soficitinib (ICP-332) Meets Primary Endpoint in Phase 3 Trial for Moderate to Severe AD

ED Treatment Gaps Persist for Pediatric Atopic Dermatitis